LPS tolerance in septic ICU patients: laboratory and technical considerations.
Myrianthefs
Pavlos
P
Styliano
Wyrta
W
Venetsanou
Kyriaki
K
Baltopoulos
George
G
D015415:Biomarkers / Q000032:analysis; D016638:Critical Illness; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000378:metabolism*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007362:Intensive Care Units; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D020714:Maximum Tolerated Dose; D011379:Prognosis; D018570:Risk Assessment; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis
D015415:Biomarkers; D016207:Cytokines; D004731:Endotoxins; D008070:Lipopolysaccharides